BETÜL YAZĞAN, Yener YAZĞAN, MUSTAFA NAZIROĞLU

Ağrı Moleküler Yolaklarında TRPV1 Katyon Kanalının Önemi

TRPV1 katyon kanalları seçici olmayan bir katyon kanalı olup, merkezi ve periferik primer duysal nöronlarda özellikle varlığı gösterilmiştir. Bu kanallar, kapsaisin (acı kırmızıbiberin keskin bileşeni) ve resiniferatoksin gibi vanilloidler, yüksek Isı (>430C), asit (pH

Importance of TRPV1 Cation Channel on Molecular Pathways of Pain

TRPV1 is a non-selective cation channel that is mostly located on central and primary afferent sensory neurons. TRPV1 is activated by noxious painful stimuli such as acid (low pH), noxious heat (>430C), voltage, components of the inflammatory, oxidative stress and vanilloids. TRPV1 has important role on detection and transmission of painful stimuli. In this review article, the authors summarize the recent information of pain literature to understand the etiology of the pain. The effects of TRPV1 on different types of neuronal pain are investigated in the laboratory and clinical trials. TRPV1 is reported to contribute to acute, chronic pain, such as osteoarthritis, neuropathic pain, migraine, bone cancer pain. It is also reported that TRPV1 takes part in pain processing and modulation, thermoregulation, osmoregulation among other functions. Activation of TRPV1 has important role on persistent cough, chronic obstructive pulmonary disease, bladder hyperactivity associated with bladder inflammation in human. TRPV1 is regulated / activated by some lipids such as phosphatidylinositolbiphosphate (PIP2) and lysophosphatidylcholine (LPA). Hence, PIP2 and LPA have been described as modulator and allosteric activator of the channel. A range of inflammatory mediators and growth or tumor factors are known to contribute to hyperalgesia via sensitization of TRPV1 through activation of kinase pathways that can lead to direct receptor phosphorylation at multiple intracellular sites. In conclusion, immunohistochemical, biophysical, pharmacological characterization of these channels might provide the intellectual and technical infrastructure for developing new classes of analgesic drugs.

___

1. Kim E, Susan M, Scott B, Heddwen L. Ganong"un Review of Medical Physiology. 23thed, New York: McGraw-Hill, 2011: 416- 18.
2. Ozgül C, Naziroglu M. Role of TRPM2 cation channels on molecular pathways in neurological cells. Journal of Experimental and Clinical Medicine 2010; 27: 144-51.
3. Feng Z, Pearce LV, Xu X, et al. Structural Insight into Tetrameric hTRPV1 from Homology Modeling, Molecular Docking, Molecular Dynamics Simulation, Virtual Screening, and Bioassay Validations. Journal of chemical information and modeling 2015; 55: 572-88.
4. Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000; 288: 306-13.
5. Szallasi A, Blumberg PM. Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor. Life sciences 1990; 47: 1399-08.
6. Cui M, Honore P, Zhong C, et al. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. The Journal of neuroscience : the official journal of the Society for Neuroscience 2006; 26: 9385-93.
7. Summ O, Holland PR, Akerman S, Goadsby PJ. TRPV1 receptor blockade is ineffective in different in vivo models of migraine. Cephalalgia : an international journal of headache 2011; 31: 172- 80.
8. Bevan S, Quallo T, Andersson DA. TRPV1. Handbook of experimental pharmacology 2014; 222: 207-45.
9. Ghazizadeh V, Naziroglu M. Electromagnetic radiation (Wi-Fi) and epilepsy induce calcium entry and apoptosis through activation of TRPV1 channel in hippocampus and dorsal root ganglion of rats. Metab Brain Dis 2014; 29: 787-99.
10. Cig B, Naziroglu M. Investigation of the effects of distance from sources on apoptosis, oxidative stress and cytosolic calcium accumulation via TRPV1 channels induced by mobile phones and Wi-Fi in breast cancer cells. Biochimica et biophysica acta 2015. [Epub ahead of print]
11. Kose SA, Naziroglu M. Selenium Reduces Oxidative Stress and Calcium Entry Through TRPV1 Channels in the Neutrophils of Patients with Polycystic Ovary Syndrome. Biol Trace Elem Res 2014; 158: 136-42.
12. De Petrocellis L, Harrison S, Bisogno T, et al. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J Neurochem 2001; 77: 1660-63.
13. Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998; 21: 531-43.
14. Steenland HW, Ko SW, Wu LJ, Zhuo M. Hot receptors in the brain. Molecular pain 2006; 2:34.
15. Kobayashi K, Fukuoka T, Obata K, et al. Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with adelta/c-fibers and colocalization with trk receptors. J Comp Neurol 2005; 493: 596-06.
16. Feng NH, Lee HH, Shiang JC, Ma MC. Transient receptor potential vanilloid type 1 channels act as mechanoreceptors and cause substance P release and sensory activation in rat kidneys. American journal of physiology Renal physiology 2008; 294: 316-25.
17. Ichikawa H, Sugimoto T. The co-expression of VR1 and VRL-1 in the rat vagal sensory ganglia. Brain research 2003; 980: 293- 96.
18. Palazzo E, Luongo L, de Novellis V, Berrino L, Rossi F, Maione S. Moving towards supraspinal TRPV1 receptors for chronic pain relief. Molecular pain 2010; 6:66.
19. Karai LJ, Russell JT, Iadarola MJ, Olah Z. Vanilloid receptor 1 regulates multiple calcium compartments and contributes to Ca2+-induced Ca2+ release in sensory neurons. The Journal of biological chemistry 2004; 279: 16377-87.
20. Poonyachoti S, Kulkarni-Narla A, Brown DR. Chemical coding of neurons expressing delta- and kappa-opioid receptor and type I vanilloid receptor immunoreactivities in the porcine ileum. Cell and tissue research 2002; 307: 23-33.
21. Ward SM, Bayguinov J, Won KJ, Grundy D, Berthoud HR. Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract. The Journal of comparative neurology 2003; 465: 121-35.
22. Anavi-Goffer S, Coutts AA. Cellular distribution of vanilloid VR1 receptor immunoreactivity in the guinea-pig myenteric plexus. European journal of pharmacology 2003; 458: 61-71.
23. Zhang Y, Xiang B, Li YM, et al. Expression and characteristics of vanilloid receptor 1 in the rabbit submandibular gland. Biochemical and biophysical research communications 2006; 345: 467-73.
24. McIntyre P, McLatchie LM, Chambers A, et al. Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br J Pharmacol 2001; 132: 1084-94.
25. Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug discovery today 2009; 14: 56-67.
26. Chou MZ, Mtui T, Gao YD, Kohler M, Middleton RE. Resiniferatoxin binds to the capsaicin receptor (TRPV1) near the extracellular side of the S4 transmembrane domain. Biochemistry 2004; 43: 2501-11.
27. Gavva NR, Klionsky L, Qu Y, et al. Molecular determinants of vanilloid sensitivity in TRPV1. The Journal of biological chemistry 2004; 279: 20283-95.
28. Yao J, Liu B, Qin F. Modular thermal sensors in temperaturegated transient receptor potential (TRP) channels. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 11109-14.
29. Grandl J, Kim SE, Uzzell V, et al. Temperature-induced opening of TRPV1 ion channel is stabilized by the pore domain. Nature neuroscience 2010; 13: 708-14.
30. Davis JB, Gray J, Gunthorpe MJ, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000; 405: 183-87.
31. De-la-Rosa V, Rangel-Yescas GE, Ladron-de-Guevara E, Rosenbaum T, Islas LD. Coarse architecture of the transient receptor potential vanilloid 1 (TRPV1) ion channel determined by fluorescence resonance energy transfer. The Journal of biological chemistry 2013; 288: 29506-17.
32. Di Marzo V, Blumberg PM, Szallasi A. Endovanilloid signaling in pain. Current opinion in neurobiology 2002; 12: 372-79.
33. Szolcsanyi J, Sandor Z. Multisteric TRPV1 nocisensor: a target for analgesics. Trends in pharmacological sciences 2012; 33: 646- 55.
34. Gavva NR. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends in pharmacological sciences 2008; 29: 550-57.
35. Srinivasan K. Biological Activities of Red Pepper (Capsicum annuum) and Its Pungent Principle Capsaicin: A Review. Critical reviews in food science and nutrition 2013. [Epub ahead of print]
36. Bohlen CJ, Julius D. Receptor-targeting mechanisms of paincausing toxins: How ow? Toxicon : official journal of the International Society on Toxinology 2012; 60: 254-64.
37. Lieben L, Carmeliet G. The Involvement of TRP Channels in Bone Homeostasis. Frontiers in endocrinology 2012; 3 :99.
38. Yoo S, Han S, Park YS, Lee JH, Oh U, Hwang SW. Lipoxygenase inhibitors suppressed carrageenan-induced Fosexpression and inflammatory pain responses in the rat. Molecules and cells 2009; 27: 417-22.
39. Palazzo E, Luongo L, de Novellis V, Rossi F, Marabese I, Maione S. Transient receptor potential vanilloid type 1 and pain development. Current opinion in pharmacology 2012; 12: 9-17.
40. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 2000; 100: 685-88.
41. Rathee PK, Distler C, Obreja O, et al. PKA/AKAP/VR-1 module: A common link of Gs-mediated signaling to thermal hyperalgesia. The Journal of neuroscience : the official journal of the Society for Neuroscience 2002; 22: 4740-45.
42. Srinivasan R, Wolfe D, Goss J, et al. Protein kinase C epsilon contributes to basal and sensitizing responses of TRPV1 to capsaicin in rat dorsal root ganglion neurons. The European journal of neuroscience 2008; 28: 1241-54.
43. Zhang X, Li L, McNaughton PA. Proinflammatory mediators modulate the heat-activated ion channel TRPV1 via the scaffolding protein AKAP79/150. Neuron 2008; 59: 450-61.
44. Vellani V, Kinsey AM, Prandini M, et al. Protease activated receptors 1 and 4 sensitize TRPV1 in nociceptive neurones. Molecular pain 2010; 6: 61.
45. Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RWt. cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 2002; 35: 721-31.
46. Moriyama T, Iida T, Kobayashi K, et al. Possible involvement of P2Y2 metabotropic receptors in ATP-induced transient receptor potential vanilloid receptor 1-mediated thermal hypersensitivity. The Journal of neuroscience : the official journal of the Society for Neuroscience 2003; 23: 6058-62.
47. Meents JE, Neeb L, Reuter U. TRPV1 in migraine pathophysiology. Trends in molecular medicine 2010; 16: 153- 59.
48. Li Y, Cai J, Han Y, et al. Enhanced function of TRPV1 via upregulation by insulin-like growth factor-1 in a rat model of bone cancer pain. European journal of pain 2014; 18: 774-84.
49. Novakova-Tousova K, Vyklicky L, Susankova K, et al. Functional changes in the vanilloid receptor subtype 1 channel during and after acute desensitization. Neuroscience 2007; 149: 144-54.
50. Lishko PV, Procko E, Jin X, Phelps CB, Gaudet R. The ankyrin repeats of TRPV1 bind multiple ligands and modulate channel sensitivity. Neuron 2007; 54: 905-18.
51. Yee JR, Kenkel W, Caccaviello JC, et al. Identifying the integrated neural networks involved in capsaicin-induced pain using fMRI in awake TRPV1 knockout and wild-type rats. Frontiers in systems neuroscience 2015; 9: 15.
52. Moylan Governo RJ, Morris PG, Prior MJ, Marsden CA, Chapman V. Capsaicin-evoked brain activation and central sensitization in anaesthetised rats: a functional magnetic resonance imaging study. Pain 2006; 126: 35-45.
53. Starowicz K, Maione S, Cristino L, et al. Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. The Journal of neuroscience : the official journal of the Society for Neuroscience 2007; 27: 13739- 49.
54. Palazzo E, Rossi F, Maione S. Role of TRPV1 receptors in descending modulation of pain. Molecular and cellular endocrinology 2008; 286: 79-83.
55. Spicarova D, Adamek P, Kalynovska N, Mrozkova P, Palecek J. TRPV1 receptor inhibition decreases CCL2-induced hyperalgesia. Neuropharmacology 2014; 81: 75-84.
56. Keeble J, Russell F, Curtis B, Starr A, Pinter E, Brain SD. Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthritis and rheumatism 2005; 52: 3248-56.
57. Li HY, Lee BK, Kim JS, Jung SJ, Oh SB. Eugenol Inhibits ATPinduced P2X Currents in Trigeminal Ganglion Neurons. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2008; 12: 315-21.
58. Nakanishi M, Hata K, Nagayama T, et al. Acid activation of Trpv1 leads to an up-regulation of calcitonin gene-related peptide expression in dorsal root ganglion neurons via the CaMK-CREB cascade: a potential mechanism of inflammatory pain. Molecular biology of the cell 2010; 21: 2568-77.
59. Yoneda T, Hiasa M, Nagata Y, Okui T, White F. Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain. Biochimica et biophysica acta 2015. [Epub ahead of print]
60. Niiyama Y, Kawamata T, Yamamoto J, Furuse S, Namiki A. SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. British journal of anaesthesia 2009; 102: 251-58.
61. Koh WU, Choi SS, Lee JH, et al. Perineural pretreatment of bee venom attenuated the development of allodynia in the spinal nerve ligation injured neuropathic pain model; an experimental study. BMC complementary and alternative medicine 2014; 14: 431.
62. Palazzo E, de Novellis V, Marabese I, et al. Interaction between vanilloid and glutamate receptors in the central modulation of nociception. Eur J Pharmacol 2002; 439: 69-75.
63. Negri L, Lattanzi R, Giannini E, et al. Impaired nociception and inflammatory pain sensation in mice lacking the prokineticin receptor PKR1: focus on interaction between PKR1 and the capsaicin receptor TRPV1 in pain behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience 2006; 26: 6716-27.
64. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. Brain research reviews 2009; 60: 267-77.
65. Ciura S, Liedtke W, Bourque CW. Hypertonicity sensing in organum vasculosum lamina terminalis neurons: a mechanical process involving TRPV1 but not TRPV4. The Journal of neuroscience : the official journal of the Society for Neuroscience 2011; 31: 14669-76.
66. Sun FJ, Guo W, Zheng DH, et al. Increased expression of TRPV1 in the cortex and hippocampus from patients with mesial temporal lobe epilepsy. J Mol Neurosci 2013; 49: 182-93.
67. Khairatkar-Joshi N, Szallasi A. TRPV1 antagonists: the challenges for therapeutic targeting. Trends in molecular medicine 2009; 15: 14-22.
68. Shang JJ, Yuan JY, Xu H, Tang RZ, Dong YB, Xie JQ. Shugandecoction relieves visceral hyperalgesia and reduces TRPV1 and SP colon expression. World journal of gastroenterology : WJG 2013; 19: 8071-77.
69. Szolcsanyi J, Mozsik G. Effects of capsaicin on the development of gastric mucosal damage by different necrotizing agents and of gastric cytoprotection by PGI2 atropine and cimetidine on rats. Acta physiologica Hungarica 1984; 64: 287-91.
70. Satyanarayana MN. Capsaicin and gastric ulcers. Critical reviews in food science and nutrition 2006; 46: 275-28.
71. Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? The Clinical journal of pain 2008; 24: 142-54.
72. Nagy I, Santha P, Jancso G, Urban L. The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. Eur J Pharmacol 2004; 500: 351-69.
73. Szallasi A, Cruz F, Geppetti P. TRPV1: a therapeutic target for novel analgesic drugs? Trends in molecular medicine 2006; 12: 545-54.
74. Gavva NR, Bannon AW, Hovland DN, et al. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. The Journal of pharmacology and experimental therapeutics 2007; 323: 128- 37.
75. Brederson JD, Kym PR, Szallasi A. Targeting TRP channels for pain relief. Eur J Pharmacol 2013; 716 : 61-76.
76. Maihofner CG, Heskamp ML. Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study. European journal of pain 2014; 18: 671-79.
77. Maihofner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Current medical research and opinion 2013; 29: 673-83.
78. Rostron RJ, Chao Y, Roberts G, Horrocks BR. Simultaneous photocharging and luminescence intermittency in silicon nanocrystals. Journal of physics Condensed matter : an Institute of Physics journal 2009; 21: 235301-08.
79. Apostolidis A, Gonzales GE, Fowler CJ. Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. European urology 2006; 50: 1299-05.
80. Guo C, Yang B, Gu W, et al. Intravesical resiniferatoxin for the treatment of storage lower urinary tract symptoms in patients with either interstitial cystitis or detrusor overactivity: a meta-analysis. Plos One 2013; 8: 82591.
81. Peng CH, Kuo HC. Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis. Urologia internationalis 2007; 78: 78-81.
82. Iadarola MJ, Mannes AJ. The vanilloid agonist resiniferatoxin for interventional-based pain control. Current topics in medicinal chemistry 2011; 11: 2171-79.
83. Brown DC, Agnello K, Iadarola MJ. Intrathecal resiniferatoxin in a dog model: Efficacy in bone cancer pain. Pain2015. [Epub ahead of print]
84. Murdoch RD, Bareille P, Denyer J, et al. TRPV1 inhibition does not prevent cold dry air-elicited symptoms in non-allergic rhinitis. International journal of clinical pharmacology and therapeutics 2014; 52: 267-76.
85. Bareille P, Murdoch RD, Denyer J, et al. The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. International journal of clinical pharmacology and therapeutics 2013; 51: 576-84.
86. Gunthorpe MJ, Rami HK, Jerman JC, et al. Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology 2004; 46: 133-49.
87. El Kouhen R, Surowy CS, Bianchi BR, et al. A-425619 [1- isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. The Journal of pharmacology and experimental therapeutics 2005; 314: 400-09.
88. Rami HK, Thompson M, Stemp G, et al. Discovery of SB- 705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorganic & medicinal chemistry letters 2006; 16: 3287-91.
89. Garcia-Martinez C, Fernandez-Carvajal A, Valenzuela B, et al. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity. The journal of pain: official journal of the American Pain Society 2006; 7: 735- 46.
90. Ghilardi JR, Rohrich H, Lindsay TH, et al. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. The Journal of neuroscience : the official journal of the Society for Neuroscience 2005; 25: 3126-31.
91. Khalid S, Murdoch R, Newlands A, et al. Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial. The Journal of allergy and clinical immunology 2014; 134: 56-62.
92. Balestra B, Vicini R, Cremon C, et al. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 2012; 24: 1118-70.
93. Chen X, Sun W, Gianaris NG, et al. Furanocoumarins are a novel class of modulators for the transient receptor potential vanilloid type 1 (TRPV1) channel. The Journal of biological chemistry 2014; 289: 9600-10.